We are live on ! Find out more
AICPI

ABG Innovation Capital Partners III Portfolio holdings

AUM $64.5K
1-Year Est. Return 1.01%
This Fund
S&P 500
This Quarter Est. Return
-5.97%
1 Year Est. Return
+1.01%
3 Year Est. Return
+5.56%
5 Year Est. Return
-85.52%
10 Year Est. Return
–
AUM
$204M
AUM Growth
+$33.7M
Cap. Flow
+$52.7M
Cap. Flow %
25.9%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$110M

Sector Composition

Rank Sector Weight
1 Healthcare 19.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUNG icon
1
Pulmonx
LUNG
$87M
$38.1M 18.73%
833,333
– –
GNCA
2
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.02M 0.5%
375,000
– –
SYBX
3
DELISTED
Synlogic
SYBX
$737K 0.36%
13,727
– –
WHWK
4
Whitehawk Therapeutics
WHWK
$205M
$516K 0.25%
26,667
– –
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$76K 0.04%
1,834
– –
ACGN
6
DELISTED
Aceragen Inc
ACGN
$73K 0.04%
3,312
– –
AVIR icon
7
Atea Pharmaceuticals
AVIR
$376M
– –
-2,639,178
Closed -$110M

Similar funds

FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
SNN
Shen Neil Nanpeng $36.3K AUM 179.45% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
MI
Motiv8 Investments Port St. Lucie, Florida $183K AUM 15.06% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
NA
Newport Asia San Francisco, California $2.21M AUM
IVSFI
IA Venture Strategies Fund II New York $4.08M AUM 174.71% 1-Year Est. Return

ABG Innovation Capital Partners III's Q1 2021 Portfolio in Review

As of Q1 2021, ABG Innovation Capital Partners III held 8 positions worth $204M, up 20% from $170M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG Innovation Capital Partners III deployed $52.7M of net new capital in Q1 2021, opening 1 new position.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 100% a quarter earlier.

On the sell side, the most notable exit was Atea Pharmaceuticals, an estimated $110M sold.

  • ABG Innovation Capital Partners III fully exited Atea Pharmaceuticals in Q1 2021, selling an estimated $110M.
  • ABG Innovation Capital Partners III's ten largest holdings make up 100% of its $204M portfolio in Q1 2021.
  • ABG Innovation Capital Partners III opened 1 new position and closed 1 in Q1 2021.
  • ABG Innovation Capital Partners III's portfolio value rose 20% quarter-over-quarter to $204M.

Based on ABG Innovation Capital Partners III's 13F filing for Q1 2021, filed 17 May 2021.